Lv1
40 积分 2021-04-11 加入
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
19天前
已完结
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
20天前
已完结
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
20天前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
20天前
已完结
Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?
21天前
已完结
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer
23天前
已完结
Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study
23天前
已完结
How Can Radiotherapy and Immunotherapy Combine for the Future of Cancer Care?
23天前
已关闭
Radiation Therapy and Immunotherapy: What is the Optimal Timing or Sequencing?
23天前
已完结
Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study
25天前
已完结
皖公网安备34019202002308
